Case study of the anemic patient: epoetin alfa--focus on CQI and patient management.
Epoetin alfa, widely used in treating the anemia caused by end-stage renal disease, provides several benefits to patients, including increased energy and an improved sense of well-being. Achieving these benefits depends on appropriate patient management. This article discusses how a multidisciplinary renal team can use continuous quality improvement principles to manage a suboptimal response to Epoetin alfa therapy caused by aluminum toxicity.
Kammerer
J K
JK
D000368:Aged; D000535:Aluminum / Q000506:poisoning*; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D010347:Patient Care Planning; D010348:Patient Care Team; D017749:Total Quality Management / Q000458:organization & administration*
D004921:Erythropoietin; D000535:Aluminum